MolecuLight garners $7.5M to expand fluorescence imaging device commercialization

MolecuLight (Toronto, ON, Canada), which has developed a handheld fluorescence imaging device for real-time visualization of bacteria for chronic wounds, has secured a $7.5 million term loan from Oxford Finance (Alexandria, VA). The financing will further support MolecuLight's commercial expansion for the growing global demand for its MolecuLight i:X device.

Related: Handheld fluorescence imager receives U.S. FDA De Novo clearance

The MolecuLight i:X fluorescence imaging device assists clinicians in visualizing clinically significant bacteria in chronic wounds in real time, digitally measuring the wounds and assisting in optimizing the treatment pathway at the point-of-care. In the U.S., the device is indicated as a handheld imaging tool that can view and digitally record images of a wound, and then view and digitally record images of fluorescence emitted from a wound when exposed to an excitation light.

For more information, please visit moleculight.com.